A citation-based method for searching scientific literature

Grażyna Söderbom, Bai-Yun Zeng. Int Rev Neurobiol 2020
Times Cited: 12







List of co-cited articles
11 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Protection of Mcc950 against high-glucose-induced human retinal endothelial cell dysfunction.
Yi Zhang, Xuehua Lv, Zizhong Hu, Xiaojian Ye, Xinhua Zheng, Yuzhi Ding, Ping Xie, Qinghuai Liu. Cell Death Dis 2017
68
16

Pharmacological Inhibitors of the NLRP3 Inflammasome.
Ayesha Zahid, Bofeng Li, Arnaud John Kombe Kombe, Tengchuan Jin, Jinhui Tao. Front Immunol 2019
268
16

A role for mitochondria in NLRP3 inflammasome activation.
Rongbin Zhou, Amir S Yazdi, Philippe Menu, Jürg Tschopp. Nature 2011
16

Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice.
Richard Gordon, Eduardo A Albornoz, Daniel C Christie, Monica R Langley, Vinod Kumar, Susanna Mantovani, Avril A B Robertson, Mark S Butler, Dominic B Rowe, Luke A O'Neill,[...]. Sci Transl Med 2018
313
16

Clinical trials of new drugs for Alzheimer disease.
Li-Kai Huang, Shu-Ping Chao, Chaur-Jong Hu. J Biomed Sci 2020
228
16

Beta-amyloid activates NLRP3 inflammasome via TLR4 in mouse microglia.
Yang Liu, Yue Dai, Qing Li, Chen Chen, Hao Chen, Yuanjian Song, Fang Hua, Zuohui Zhang. Neurosci Lett 2020
41
16

CBP gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer's disease.
Antonella Caccamo, Monica A Maldonado, Alex F Bokov, Smita Majumder, Salvatore Oddo. Proc Natl Acad Sci U S A 2010
174
16

Accelerated progression from mild cognitive impairment to dementia in people with diabetes.
Weili Xu, Barbara Caracciolo, Hui-Xin Wang, Bengt Winblad, Lars Bäckman, Chengxuan Qiu, Laura Fratiglioni. Diabetes 2010
136
16

Human cerebral neuropathology of Type 2 diabetes mellitus.
Peter T Nelson, Charles D Smith, Erin A Abner, Frederick A Schmitt, Stephen W Scheff, Gregory J Davis, Jeffrey N Keller, Gregory A Jicha, Daron Davis, Wang Wang-Xia,[...]. Biochim Biophys Acta 2009
129
16

Targeting the microglial NLRP3 inflammasome and its role in Parkinson's disease.
Md Ezazul Haque, Mahbuba Akther, Md Jakaria, In-Su Kim, Shofiul Azam, Dong-Kug Choi. Mov Disord 2020
90
16

The metabolic syndrome, inflammation, and risk of cognitive decline.
Kristine Yaffe, Alka Kanaya, Karla Lindquist, Eleanor M Simonsick, Tamara Harris, Ronald I Shorr, Frances A Tylavsky, Anne B Newman. JAMA 2004
707
16

Human Trials of Stem Cell-Derived Dopamine Neurons for Parkinson's Disease: Dawn of a New Era.
Roger A Barker, Malin Parmar, Lorenz Studer, Jun Takahashi. Cell Stem Cell 2017
190
8

Immunosuppressants and risk of Parkinson disease.
Brad A Racette, Anat Gross, Scott Martin Vouri, Alejandra Camacho-Soto, Allison W Willis, Susan Searles Nielsen. Ann Clin Transl Neurol 2018
42
8



Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic.
S Pablo Sardi, Jesse M Cedarbaum, Patrik Brundin. Mov Disord 2018
102
8

The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson's Disease.
Lingyu Zhang, Liping Zhang, Yanwei Li, Lin Li, Josefine Ulrikke Melchiorsen, Mette Rosenkilde, Christian Hölscher. J Parkinsons Dis 2020
37
8

Dementia-Related Functional Disability in Moderate to Advanced Parkinson's Disease: Assessment Using the World Health Organization Disability Assessment Schedule 2.0.
Jia-Hung Chen, Chien-Tai Hong, Dean Wu, Wen-Chou Chi, Chia-Feng Yen, Hua-Fang Liao, Lung Chan, Tsan-Hon Liou. Int J Environ Res Public Health 2019
8
12

Cholestatic liver diseases: new targets, new therapies.
Priscila Santiago, Andrew R Scheinberg, Cynthia Levy. Therap Adv Gastroenterol 2018
45
8

Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study.
Ryan W Dellinger, Santiago Roel Santos, Mark Morris, Mal Evans, Dan Alminana, Leonard Guarente, Eric Marcotulli. NPJ Aging Mech Dis 2017
84
8

Peripheral-Central Neuroimmune Crosstalk in Parkinson's Disease: What Do Patients and Animal Models Tell Us?
Marie Therese Fuzzati-Armentero, Silvia Cerri, Fabio Blandini. Front Neurol 2019
36
8


A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway.
Dong Seok Kim, Ho-Il Choi, Yun Wang, Yu Luo, Barry J Hoffer, Nigel H Greig. Cell Transplant 2017
76
8

Parkinson's Disease Multimodal Complex Treatment improves motor symptoms, depression and quality of life.
Raphael Scherbaum, Elke Hartelt, Manuel Kinkel, Ralf Gold, Siegfried Muhlack, Lars Tönges. J Neurol 2020
19
8

Clinical utility of DaTscan™ (123I-Ioflupane Injection) in the diagnosis of Parkinsonian Syndromes.
Andreas-Antonios Roussakis, Paola Piccini, Marios Politis. Degener Neurol Neuromuscul Dis 2013
5
20

Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease.
Alan L Whone, Mihaela Boca, Matthias Luz, Max Woolley, Lucy Mooney, Sonali Dharia, Jack Broadfoot, David Cronin, Christian Schroers, Neil U Barua,[...]. J Parkinsons Dis 2019
72
8

Inflammatory bowel disease increases the risk of Parkinson's disease: a Danish nationwide cohort study 1977-2014.
Marie Villumsen, Susana Aznar, Bente Pakkenberg, Tine Jess, Tomasz Brudek. Gut 2019
145
8

Molecular changes in the postmortem parkinsonian brain.
Damien Toulorge, Anthony H V Schapira, Rodolphe Hajj. J Neurochem 2016
59
8

Metabolic Correlates of Dopaminergic Loss in Dementia with Lewy Bodies.
Maria Huber, Leonie Beyer, Catharina Prix, Sonja Schönecker, Carla Palleis, Boris-Stephan Rauchmann, Silvia Morbelli, Andrea Chincarini, Rose Bruffaerts, Rik Vandenberghe,[...]. Mov Disord 2020
25
8

Potential neuroprotective effect of ibuprofen, insights from the mice model of Parkinson's disease.
Maciej Swiątkiewicz, Małgorzata Zaremba, Ilona Joniec, Andrzej Członkowski, Iwona Kurkowska-Jastrzębska. Pharmacol Rep 2013
29
8

Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial.
C R A Silveira, J MacKinley, K Coleman, Z Li, E Finger, R Bartha, S A Morrow, J Wells, M Borrie, R G Tirona,[...]. BMC Neurol 2019
68
8


Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
Andrew J Lees, Joaquim Ferreira, Olivier Rascol, Werner Poewe, José-Francisco Rocha, Michelle McCrory, Patricio Soares-da-Silva. JAMA Neurol 2017
77
8

Dementia in Parkinson's disease is associated with enhanced mitochondrial complex I deficiency.
Ariana P Gatt, Olivia F Duncan, Johannes Attems, Paul T Francis, Clive G Ballard, Joseph M Bateman. Mov Disord 2016
52
8

Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations.
Benjamin Dehay, Mathieu Bourdenx, Philippe Gorry, Serge Przedborski, Miquel Vila, Stephane Hunot, Andrew Singleton, C Warren Olanow, Kalpana M Merchant, Erwan Bezard,[...]. Lancet Neurol 2015
279
8

MECHANISMS IN ENDOCRINOLOGY: SGLT2 inhibitors: clinical benefits by restoration of normal diurnal metabolism?
Russell L Esterline, Allan Vaag, Jan Oscarsson, Jiten Vora. Eur J Endocrinol 2018
52
8

Iron accumulation confers neurotoxicity to a vulnerable population of nigral neurons: implications for Parkinson's disease.
Scott Ayton, Peng Lei, Paul A Adlard, Irene Volitakis, Robert A Cherny, Ashley I Bush, David I Finkelstein. Mol Neurodegener 2014
43
8

Administration of MPTP to the common marmoset does not alter cortical cholinergic function.
J Garvey, M Petersen, C M Waters, S P Rose, S Hunt, R Briggs, P Jenner, C D Marsden. Mov Disord 1986
11
9

Frequency of Loss of Function Variants in LRRK2 in Parkinson Disease.
Cornelis Blauwendraat, Xylena Reed, Demis A Kia, Ziv Gan-Or, Suzanne Lesage, Lasse Pihlstrøm, Rita Guerreiro, J Raphael Gibbs, Marya Sabir, Sarah Ahmed,[...]. JAMA Neurol 2018
50
8


Reduced Risk of Parkinson Disease in Patients With Rheumatoid Arthritis: A Nationwide Population-Based Study.
Yueh-Feng Sung, Feng-Cheng Liu, Chun-Chieh Lin, Jiunn-Tay Lee, Fu-Chi Yang, Yu-Ching Chou, Cheng-Li Lin, Chia-Hung Kao, Hsin-Yi Lo, Tse-Yen Yang. Mayo Clin Proc 2016
27
8

Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease.
Rattanavijit Vijitruth, Mei Liu, Dong-Young Choi, Xuan V Nguyen, Randy L Hunter, Guoying Bing. J Neuroinflammation 2006
178
8


Benefits of Vitamins in the Treatment of Parkinson's Disease.
Xiuzhen Zhao, Ming Zhang, Chunxiao Li, Xue Jiang, Yana Su, Ying Zhang. Oxid Med Cell Longev 2019
39
8

Parkinson's Disease Biomarkers: Where Are We and Where Do We Go Next?
Lana M Chahine, Matthew B Stern. Mov Disord Clin Pract 2017
9
11

CSF or serum neurofilament light added to α-Synuclein panel discriminates Parkinson's from controls.
Linda P Oosterveld, Inge M W Verberk, Nour K Majbour, Omar M El-Agnaf, Henry C Weinstein, Henk W Berendse, Charlotte E Teunissen, Wilma D J van de Berg. Mov Disord 2020
39
8

Parkinson's disease as a result of aging.
Manuel Rodriguez, Clara Rodriguez-Sabate, Ingrid Morales, Alberto Sanchez, Magdalena Sabate. Aging Cell 2015
111
8

Role of Neuroinflammation in Parkinson Disease: The Enigma Continues.
Shyamal H Mehta, Caroline M Tanner. Mayo Clin Proc 2016
9
11

Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain.
Latha Devi, Vijayendran Raghavendran, Badanavalu M Prabhu, Narayan G Avadhani, Hindupur K Anandatheerthavarada. J Biol Chem 2008
698
8

Exenatide Regulates Cerebral Glucose Metabolism in Brain Areas Associated With Glucose Homeostasis and Reward System.
Giuseppe Daniele, Patricia Iozzo, Marjorie Molina-Carrion, Jack Lancaster, Demetrio Ciociaro, Eugenio Cersosimo, Devjit Tripathy, Curtis Triplitt, Peter Fox, Nicolas Musi,[...]. Diabetes 2015
37
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.